Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy …
MH Einstein, MJ Levin, A Chatterjee… - Human vaccines & …, 2014 - Taylor & Francis
We previously reported higher anti-HPV-16 and-18 immune responses induced by HPV-
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy …
MH Einstein, MJ Levin, A Chatterjee… - Human vaccines & …, 2014 - pubmed.ncbi.nlm.nih.gov
We previously reported higher anti-HPV-16 and-18 immune responses induced by HPV-
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy …
MH Einstein, MJ Levin, A Chatterjee… - Human Vaccines & …, 2014 - ingentaconnect.com
We previously reported higher anti-HPV-16 and-18 immune responses induced by HPV-
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
[引用][C] Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in …
MH Einstein, MJ Levin, A Chatterjee… - Human Vaccines & …, 2014 - cir.nii.ac.jp
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18
AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years …
AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years …
[PDF][PDF] Francis J Dessy5, Philippe Moris5, Lan Lin6, Frank Struyf5, and Gary Dubin7, on behalf of the HPV-010 Study Group
MH Einstein, MJ Levin, A Chatterjee, N Chakhtoura… - Citeseer
Persistent infection with an oncogenic human papillomavirus (HPV) is a necessary cause of
invasive cervical cancer. 1 HPV infections are frequently acquired soon after initiation of …
invasive cervical cancer. 1 HPV infections are frequently acquired soon after initiation of …
[PDF][PDF] Francis J Dessy5, Philippe Moris5, Lan Lin6, Frank Struyf5, and Gary Dubin7, on behalf of the HPV-010 Study Group
MH Einstein, MJ Levin, A Chatterjee, N Chakhtoura… - scienceopen.com
Persistent infection with an oncogenic human papillomavirus (HPV) is a necessary cause of
invasive cervical cancer. 1 HPV infections are frequently acquired soon after initiation of …
invasive cervical cancer. 1 HPV infections are frequently acquired soon after initiation of …
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy …
MH Einstein, MJ Levin, A Chatterjee… - Human vaccines & …, 2014 - scholarship.miami.edu
CI, confidence interval CVS, cervicovaginal secretion PBMC, peripheral blood mononuclear
cells NOAD, new onset autoimmune disease 50 μg) adsorbed on aluminum salt (500 μg Al …
cells NOAD, new onset autoimmune disease 50 μg) adsorbed on aluminum salt (500 μg Al …
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy …
MH Einstein, MJ Levin, A Chatterjee… - Human Vaccines …, 2014 - einstein.elsevierpure.com
We previously reported higher anti-HPV-16 and-18 immune responses induced by HPV-
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
[HTML][HTML] Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine …
MH Einstein, MJ Levin, A Chatterjee… - Human Vaccines & …, 2014 - ncbi.nlm.nih.gov
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18
AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years …
AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years …
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy …
MH Einstein, MJ Levin, A Chatterjee… - Human Vaccines …, 2014 - researchwithrutgers.com
We previously reported higher anti-HPV-16 and-18 immune responses induced by HPV-
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …